|
gptkbp:instanceOf
|
gptkb:muscarinic_antagonist
gptkb:alkaloid
gptkb:anticholinergic_drug
|
|
gptkbp:ATCCode
|
A04AD01
|
|
gptkbp:boilingPoint
|
not applicable (decomposes)
|
|
gptkbp:CASNumber
|
51-34-3
|
|
gptkbp:category
|
gptkb:World_Health_Organization_essential_medicines
|
|
gptkbp:chemicalFormula
|
C17H21NO4
|
|
gptkbp:contraindication
|
gptkb:myasthenia_gravis
gptkb:glaucoma
prostatic hypertrophy
|
|
gptkbp:discoveredBy
|
gptkb:Albert_Ladenburg
|
|
gptkbp:discoveredIn
|
1880
|
|
gptkbp:eliminationHalfLife
|
8 hours
|
|
gptkbp:excretion
|
renal
|
|
gptkbp:foundIn
|
gptkb:Datura_stramonium
gptkb:Atropa_belladonna
gptkb:Hyoscyamus_niger
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
muscarinic acetylcholine receptor antagonist
|
|
gptkbp:meltingPoint
|
59–61 °C
|
|
gptkbp:metabolism
|
hepatic
|
|
gptkbp:molecularWeight
|
303.35 g/mol
|
|
gptkbp:otherName
|
gptkb:hyoscine
|
|
gptkbp:pregnancyCategory
|
C (US)
|
|
gptkbp:PubChem_CID
|
CHEMBL651
5184
DB00747
|
|
gptkbp:risk_of_overdose
|
delirium
coma
seizures
|
|
gptkbp:routeOfAdministration
|
oral
transdermal
intravenous
|
|
gptkbp:sideEffect
|
confusion
blurred vision
drowsiness
hallucinations
dry mouth
|
|
gptkbp:solubility
|
soluble in water
|
|
gptkbp:UNII
|
577I1CFA9H
|
|
gptkbp:used_in
|
treatment of irritable bowel syndrome
palliative care for reducing respiratory secretions
preanesthetic medication
|
|
gptkbp:usedFor
|
motion sickness
postoperative nausea and vomiting
|
|
gptkbp:bfsParent
|
gptkb:Burundanga
gptkb:Antiemetics
gptkb:Hallucinogenic_Plants
|
|
gptkbp:bfsLayer
|
7
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Scopolamine
|